2nd EuroSciCon Conference on

Biosimilars and Biologics 2020

Theme: New Horizons in Biosimilars and Biologics Early Bird Registration is closing Soon! DO NOT MISS OUT!

Event Date & Time

Event Location

Amsterdam, Netherlands

18 years of lifescience communication

17345684571

Performers / Professionals From Around The Globe

Conference Speaker

MARCEL DEN HARTOG

Director Cell Line Development bij Bioceros BV
Netherlands

Conference Speaker

KLARA VALKO

UCL School of Pharmacy, London, UK.
UK

Conference Speaker

ZAFER GUNEY

GUTF Medical Pharmacology, President, Biotechnological drugs society, M.D. Clinical Pharmacologist
Turkey

Conference Speaker

MITSUJI YAMASHITA

Shizuoka University, Japan
Japan

Conference Speaker

THOMAS D. BANNISTER

The Scripps Research Institute, Florida United States
USA

Conference Speaker

SOLIMAN KHATIB

MIGAL Galilee Technology Center -Tel Hai College, Israel
Israel

Tracks & Key Topics

Biosimilars 2020

About Conference

Registration and abstract submission now open

On behalf of Biosimilars and Biologics Organizing Committee, we are pleased to invite researchers, academicians, counselors, educators, research scientists, self-help group facilitators, teachers, business delegates, young researchers and industrialists to give the world a better solution to this problem. The conference will be a platform to globalize one research, to share scientific experience and to gain knowledge on new methods and treatment procedures with Biosimilars and Biologics. The 2nd International Conference on Biosimilars and Biologics which is going to be held on February 19-20, 2020 at Amsterdam, Netherlands. The conference highlights the theme of “New Horizons in Biosimilars and Biologics”.

The scientific program includes Keynote & Plenary talks, Video Presentations, Poster Presentations, and E-Posters. Furthermore, oral communications of (post)doctoral junior scientists will be considered. It is the goal of the organizers to make this meeting an event of scientific excellence, attractive to both industrial and academic scientists in Cardiology and its advancements.

We invite sponsors and exhibitor to showcase your products to our participants and make it reach the public through them. We request you to make use of this opportunity to make the world a better place to live in.

EuroSciCon is the longest running independent life science events company with a predominantly academic client base. Our multi-professional and multi-specialty approach creates a unique experience that cannot be found with a specialist society or commercially.

Euroscicon are corporate members of the following organizations

  • Royal Society of Biology
  • IBMS
  • British Society for Immunology
  • Rare Care UK
  • Opportunities for Conference Attendees

For Researchers &Faculty:

  • Speaker Presentations
  • Poster Display
  • Symposium hosting
  • Workshop organizing

For Universities, Associations & Societies:

  • Association Partnering
  • Collaboration proposals
  • Academic Partnering
  • Group Participation

For Students & Research Scholars:

  • Poster Competition (Winner will get Best Poster Award)
  • Young Researcher Forum (YRF Award to the best presenter)
  • Student Attendee
  • Group Registrations

For Business Delegates:

  • Speaker Presentations
  • Symposium hosting
  • Book Launch event
  • Networking opportunities
  • Audience participation

For Companies:

  • Exhibitor and Vendor Booths
  • Sponsorships opportunities
  • Product launch
  • Workshop organizing
  • Scientific Partnering
  • Marketing and Networking with clients

Euroscicon organizes International Biosimilars Meetings annually across Europe, Austria, Ireland, Germany, France, Liechtenstein, Lithuania, Finland, Luxembourg, Hungary, Italy, Norway, Poland, Denmark, Macedonia, Greece, Portugal, Romania, Czech Republic, Switzerland, United Kingdom, Belgium, Scotland, Latvia, Ukraine, Sweden, Denmark, Spain, Netherlands Russia, Bulgaria, France, with solitary subject of quickening logical revelations. 

Conference Topics

About Amsterdam, Netherlands

The most crowded region of Amsterdam is the capital of the Netherlands. Amsterdam has a populace of 2,410,960 individuals. The city is situated in the territory of North Holland in the west of the nation yet isn’t its capital, which is Haarlem. The city square territory includes a piece of the Randstad, one of the bigger conurbations in Europe, with a populace of around 7 million. Starting as a little angling town in the late twelfth century, Amsterdam ended up plainly a standout amongst the most essential ports on the planet amid the Dutch Golden Age, an aftereffect of its creative improvements in exchange.

As the business capital of the Netherlands and one of the best budgetary focuses in Europe, Amsterdam is viewed as an alpha world city by the Globalization and World Cities (GaWC) ponder gathering. The city is likewise the social capital of the Netherlands. Numerous extensive Dutch organizations have their central command there, and seven of the world’s 500 biggest organizations, including Philips and ING, are situated in the city. Amsterdam was positioned the second best city to live in by the Economist Intelligence Unit and the twelfth on nature of living for condition and foundation by Mercer. The city was positioned third in development by Australian advancement office to think now in their Innovation Cities Index 2009. The Amsterdam seaport right up ‘til the present time remains the second in the nation and the fifth biggest seaport in Europe. Well, known people groups of the Amsterdam are the diarist Anne Frank, craftsmen Rembrandt van Rijn and Vincent van Gogh, and thinker Baruch Spinoza.

 

 

Sessions and Tracks

Current Challenges in Developing Biosimilars

The development of biologics calls for overcoming lot many challenges. As comparisons are being drawn from the initial stages, it is very important to have proper scientific as well as strategic approached taken for the successful development of these Biosimilars. The need for overcoming the challenges continues till the late clinical steps, drug safety factors and labelling requirements. Also it is much required now to develop a drug product in accordance to quality by design (QbD).

  • Approval Process for Biosimilar Products
  • Clinical Trial Design
  • New Trends in Delivery Systems
  • Improving the Drug Performance

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Biosimilars in Therapeutics

Biosimilars Market is experiencing a growth at an exponential rate. With the effectiveness of biosimilars and its cheap price, biosimilars is in huge demand in the pharmaceutical market. With the advancement of Biosimilars, disease management has become comparatively easier.  It is currently being used in the treatment of ailments like psoriasis, rheumatic arthritis, cancers, inflammatory bowel disease (IBD) etc. Biosimilar insulin’s have already started revolutionizing the future drug development in the realm of diabetology.  

  • Biosimilars for Cancer Treatment
  • Biosimilars for Immune Disorder Treatment
  • Monoclonal Antibody Biosimilars
  • Erythropoietin Biosimilars

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Clinical Trials of Biosimilars

As the demand of Biosimilars is ever increasing in the pharmaceutical market, it is very important to check them properly before releasing it to the mass. That is why there is a stepwise approach towards clinical trials of Biosimilars. It has various levels such as Extensive Molecular characterization Program, Pre-Clinical, Phase 1, Phase 3, Phase 4 and so on.

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Biosimilars in Oncology

Cancer is something which if treated properly is not hard to beat. Most of the medicines that we currently have for Cancer are way too costly for any common human being, but Cancer being one of the largest causes of death needs proper treatment. This is where Biosimilars come handy. Biosimilars being cheaper can increase access worldwide to potentially lifesaving biologics.

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Monoclonal Antibody Biosimilars

Monoclonal antibodies (mAbs) are natural specialists that are broadly used to treat malignancies including non-Hodgkin's lymphomas and ceaseless lymphocytic leukaemia. They are compelling however costly. The licenses for some, mAbs are lapsing, so Biosimilar solutions, which contain an adaptation of the dynamic element of the first medication, are being produced. The first mAb biosimilars to be approved in Europe and elsewhere was the infliximab biosimilars (Inflectra and Remsima), which originator is Remicade.

  • Monoclonal Antibodies in Oncology
  • Lymphatic Disorder Treatment
  • Rheumatoid Arthritis Treatment
  • Guidelines for Monoclonal Antibody Production

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Drug Development and Delivery

Drug development is the process of bringing a new pharmaceutical drug to the market once the led component has been identified through the process of drug discovery. It further has pre-clinical and clinical development procedure. Once the drug has been developed, it is important to check its mode of function, this is termed as the drug delivery.  Once this has been done, the drug can be qualified for usage.  

  • New Approaches to Enhance Drug Performance
  • Drug Delivery Companies and Markets
  • Drug Delivery Companies and Market Strategies
  • Drug Delivery Technologies

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Biopharmaceuticals

A biopharmaceutical is also known as a biologic or biological medical product. It is any pharmaceutical drug product which is manufactured in, extracted from, or semi synthesized from biological sources. They are different from totally synthesized pharmaceuticals. They include vaccines, blood and blood components, allergenic, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. 

  • Biopharmaceutical Research
  • Recombinant Protein Expression
  • Monoclonal Antibodies
  • Biologic Drug Development

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Biosimilars Pipeline

Biosimilars is a Biologic therapeutic item which is duplicate of a unique item that is made by an alternate organization. Biosimilars are formally affirmed creative adaptations of unique items, and can be made when the first item's patent terminates. Reference to the innovator product is an integral component of the approval. 

  • Economic Aspects Towards Biosimilars
  • Cost and Risk Management
  • Global Impact of Biosimilars Over Generics
  • Monitoring the Production of Biological Products

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Biosimilar Switch

Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionised the therapeutic management of inflammatory rheumatic diseases with dramatic clinical improvement and reduction in systemic inflammation in arthritis.

  • Reasons of Switching
  • Immunogenicity
  • Switching of bDMARD to its Biosimilars
  • Switches in Clinical Trails

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Biological Products

Biological Products means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein or analogous product, or arsphenamine or derivative of arsphenamine, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Biosimilar Biological Products
  • Conceptual Development of Biosimilars
  • Drug Designing
  • Drug Development

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Bioequivalence Assessment

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has most extreme significance in setting to the way that lone an appropriately bioequivalent sedate competitor that adjusts the outcomes in all regards to the first authorized item can be called as Biosimilar tranquilize.

  • Strategies for the Bioequivalence Assessment of Topical Dosage Forms
  • Evaluation of Highly Variable Drugs and Drug Products
  • Bioequivalence Approaches for Transdermal Dosage Forms
  • Bioequivalence Assessment of Respiratory Dosage Form

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Challenges in Pharmacovigilance

This session of the Biosimilars 2020 will be looking into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post market issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies. Current challenges in pharmacovigilance, Adverse drug reactions with pharmaceutical products, Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology.

  • Role of Pharma Industries in the Improvement of Pharmacovigilance System
  • Current Problems in Biosimilar Pharmacovigilance
  • Detection and Evaluation of Drug Safety Signals
  • Pharmacoepidemiology and GMP

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Intellectual Property Rights

The safeguarding of product trade secret, its formulations and other process parameters by law is usually covered by IPR. It includes those as patents, copyrights, industrial design rights, trademarks etc. IPR is of prime importance in the field of biologics and biosimilars. Most scientist and industries tend to retain their monopoly business by exercising the IPR. The very name Biosimilars calls for the occurrence of Intellectual Property rights laws and by-laws. Hence this session is of utmost interest to the attorneys and law personnel.

  • Critical Research Issues
  • Patentable Subject Matter
  • Criteria for Patentability and Patent Claim
  • Pharma Patent Scenario

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Regulatory Approach for Biosimilars

Biosimilars are the generic version of biological. It is the new buzz word in pharmaceutical industry. Biosimilars are highly similar to licensed reference product not withstanding minor differences in clinically inactive components; also there are no clinically meaningful differences between the biologicals and the reference product in terms of safety, purity, and potency.

  • Licensing of biosimilars
  • Biosimilars Regulation
  • Patent issues
  • Bio waiver approval for Biosimilars

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Globalization of Biosimilars

Globalization of Biosimilars tells us about the generic drugs impact on global biosimilars market, Cost and risk management, and Adopting innovative mechanisms such as risk-sharing arrangement, and European market for biosimilars. The global market scenario with the launch of first biosimilars in the market forecasts some radical changes. Globalization of Biosimilars will look upon such key concerns which are witnessed by the global pharma market and that are coming up with the subsequent launch of the other biosimilars and biologics.

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Biosimilars Development in Markets

A Biosimilars bio therapeutic item is comparative (but not identical) as far as quality, wellbeing, and viability to an effectively authorized reference item. Not at all like nonspecific little particles, it’s hard to institutionalize such naturally complex items in light of convoluted assembling forms. Biologics are among the most elevated cost medicines on the worldwide market today, which suggests the requirement for minimal effort choices. In developing markets, biosimilars officially offer more moderate costs, which are alluring, as well as crucial to economies where costly medications are not monetarily achievable.

  • Contribution of Biosimilars in Global Market
  • Growth of Erythropoietin Biosimilar Drug Market
  • Cloning of Genes for Erythropoietin Biosimilars
  • Rise in Biosimilar Use   

 

Biosimilars Conferences | World Biosimilars Congress | Biologic Conferences | World Biosimilars Conference 2020 | Biologic Congress | World Pharma Conference  2020 | World Pharma Congress

 

Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Sponsors/Exhibitors

A huge thanks to all our amazing partners. We couldn’t have a conference without you!